Safety aspects of SGLT2 inhibitors for treatment of heart failure

Understanding the safety profile of a drug is essential for the treatment of patients with heart failure in order for HCPs and patients to be aware of the potential risks and benefit of a treatment option. This module details the safety profile of SGLT2 inhibitors and the effects for patients with HF.

Safety aspects of SGLT2 inhibitors for treatment of heart failure
Rate this content
  • Safety aspects of SGLT2 inhibitors for treatment of heart failure
  • Safety aspects of SGLT2 inhibitors for treatment of heart failure
  • Safety profile of SGLT2 inhibitors in CVOTs in patients with T2D and high CV risk or eCVD
  • DAPA-HF: safety profile in patients with HFrEF
  • Serious AEs and prespecified AEs of interest observed in the EMPEROR-Reduced trial in patients with HFrEF
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go